May 04th – 06th 2017

Workshop & Symposium

„Tumor Immunology meets Oncology XIII“

Institute of Medical Immunology
Prof. Dr. Barbara Seliger

WELCOME TO HALLE (SAALE)
Dear colleagues and friends,

once again it is a great pleasure to welcome you in Halle for our meeting „Tumor immunology meets oncology (TIMO XIII)“, which started 13 years ago and has grown steadily over the years. We expect an exceptional participation this year due to the growth the field is currently experiencing.

The meeting focusses on immune escape mechanisms, immune tolerance, the role of immune effector and suppressor cells as well as the tumor microenvironment. In addition, the modes and efficacy of different cancer immunotherapeutic strategies alone or in combination as well as its influence on immune escape, immune suppression and resistance will be an important topic.

This meeting attracts a broad range of scientists as well as clinicians and will bridge basic, translational as well as clinical research. Although some cancer immunotherapies have recently been successfully implemented for the treatment of many cancers including mammary carcinoma, small cell lung carcinoma, colorectal cancer, kidney cancer and melanoma, there is still much to do in order to increase therapy efficacy and reprogram immune escape mechanisms. This meeting brings together an extraordinary group of international and national scientists and clinicians and represents also the basis of the working group “Tumor immunology” of the German Society of Immunology with the aim to understand anti-tumor immune responses, to treat different tumor entities with distinct immunotherapeutic approaches and to promote young scientists/clinicians to present their own work.

We would like to thank you for coming to Halle and we hope that you leave with impressions of the beauty and hospitality of the city as well as get novel insights for your own basic and translational research.

I express my gratitude to all who were involved in the organization of this event. Thank you for the meeting attendees to join us.

General information

Registration package are ready for pick-up at the TIMO registration desk located in the lobby of Building 6, Lecture Hall. Faculties are required to upload their presentation no later than half an hour before the session starts in the lecture hall.

Poster session will be at the 5th of May 2017 from 12.40 to 2.00 p.m. and offers an opportunity for continued network and provides education in a relaxed atmosphere where attendees can interact with poster presentors one by one.
**Workshop program „Tumor immunology”**

**Date:** 04\(^{th}\) of May 2017  
**Venue:** University Hospital Halle, Building 6, Lecture Hall  
Ernst-Grube-Straße 40, 06120 Halle

12.00 – 12.15 p.m.  
Introduction  
Barbara Seliger

**NEWS OF TUMOR IMMUNOLOGY**  
Chair: Elfriede Nößner (Munich)  
Marc Schmitz (Dresden)

12.15 – 12.30 p.m.  
Immune modulatory effects of biglycan on tumor cells  
Karthik Subbarayan (Halle, GER)

12.30 – 12.45 p.m.  
Kallikrein-related peptidases are potent activators of the CC-chemokine CCL14  
Mario Grünberg (Köthen, GER)

12.45 – 01.00 p.m.  
Nur77 deficiency alters dendritic cell function  
Marleen Ansems (Nijmegen, NL)

01.00 – 01.15 p.m.  
Immune modulating receptors inhibit adaptive immune response in breast cancer  
Franziska Wuerfel (Erlangen, GER)

01.15 – 01.30 p.m.  
Antigen-specific interaction with activated CD4+ T cells induces M1 associated gene expression in M2 polarized macrophages  
David Eisel (Heidelberg, GER)

01.30 – 01.45 p.m.  
Mitochondrial dysregulation and glycolytic insufficiency impair function of CD8+ T cells infiltrating human renal cell carcinoma  
Peter Siska (Regensburg, GER)

01.45 – 02.00 p.m.  
p53 isoform delta133: a new transcriptional enhancer of T cell effector function  
Kevin Legscha (Mainz, GER)

02.00 – 02.15 p.m.  
Neo-antigenic and immune cell profiling of follicular lymphoma after in situ immunotherapy  
Muhammad Ali (Oslo, NOR)

02.15 – 02.30 p.m.  
The role of T cells for the therapeutic effect of immune checkpoint inhibitors in a murine model of B cell lymphoma  
Fatima Ahmetlić (Munich, GER)

02.30 – 02.45 p.m.  
Tumor glycolipids determine immunogenicity by modulating accessibility of immune modulating surface proteins  
Antonius de Waard (Amsterdam, NL)

02.45 – 03.00 p.m.  
A whole cell vaccine in a transplantable model of ovarian cancer leads to persisting immunity  
Volker Boehnert (Bonn, GER)

03.00 – 03.30 p.m. Coffee break

**METHODS AND MORE NEWS**  
Chair: Claudia Wickenhauser (Halle)  
Stefan Eichmüller (Heidelberg)

03.30 – 03.45 p.m.  
Making T cells more resistant to repression: CAR modified T cells modulate their environment  
Viktoria Golumba-Nagy (Cologne, GER)

03.45 – 04.00 p.m.  
Increased CD8+ T cell infiltrates and PD-L1 positive cells in NSCLC correlate with better patient’s survival  
Julia Stump (Munich, GER)
04.00 – 04.15 p.m.
Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology
Antje Tunger (Dresden, GER)

04.15 – 04.30 p.m.
Spatially resolved, multiplexed digital characterization of protein and RNA expression in FFPE tissue sections
Biserka Bacic (Diessen, GER)

04.30 – 04.45 p.m.
Deciphering the biology that drives response to immunotherapy
Björn Wendik (Rodgau, GER)

04.45 – 05.00 p.m.
Delivery of mRNA using the Viromer® system
Steffen Panzner (Halle, GER)

05.00 – 05.15 p.m.
Patient stratification and therapy response prediction for anti-PD-1 therapy using plasma biomarker signature
Camille Lowy (Heidelberg, GER)

05.15 – 05.30 p.m.
Validation of novel continuous live-cell assays for immune cell activation and killing of blood cell cancers
Annedore Respa (Hertfordshire, UK)

05.30 – 05.45 p.m.
Epigenetic markers of immune cells used for immune monitoring
Thomas Kleen (Miami, USA)

05.45 – 06.00 p.m.
Primary checkpoint resistance from circulating proteins
Heinrich Röder (Boulder, USA)

Summary: Michael Bachmann (Dresden)
12.00 – 12.30 p.m.
Imiquimod inhibits mitochondrial complex I for K⁺ efflux-independent NLRP3 inflammasome activation and cancer cell growth arrest
Olaf Groß (Munich, GER)

12.30 – 12.45 p.m.
Langerhans cells in the context of human papilloma-virus infection — an aspect of virus-host-interactions
Ingeborg Zehbe (Thunder Bay, CDN)

12.45 – 02.00 p.m.
LUNCH BREAK AND POSTER SESSION
Chair: Greta Guarda / Robbert Spaapen

Session: Immune escape and immune responses
Chair: Oliver Gross / Marina Kreutz

02.00 – 02.30 p.m.
Genome-editing strategies identify glycolipid regulation of functional MHC class I on tumor cells
Robbert Spaapen (Amsterdam, NL)

02.30 – 03.00 p.m.
Novel mechanisms regulating cytotoxic T cell responses
Greta Guarda (Epalinges, CH)

03.00 – 03.30 p.m.
Interferon-γ pathway and immune escape of tumors
Barbara Seliger (Halle, GER)

03.30 – 04.00 p.m. Coffee break

Session: Tumor microenvironment and immunity
Chair: Michael Bachmann / Tanja de Gruijl

04.00 – 04.30 p.m.
Tumor-derived lactic acid promotes tumor growth via inhibition of interferon-γ production by T cells and NK cells
Marina Kreutz (Regensburg, GER)

04.30 – 05.00 p.m.
Targeting immune suppression in the leukaemia microenvironment
Sergio Rutella (Nottingham, UK)

05.00 – 05.30 p.m.
Cytosolic viral sensing pathways as regulatory targets for antiviral and vaccine development
John Hiscott (Rome, I)

07.00 – 08.00 p.m.
RECEPTION AT THE CITY MUSEUM
**REGISTRATION FEE:**

150 € - payable until 21st of April 2017 or cash at the registration desk - **Vouchers are required for registration.** MLU members will be charged for 50 €, students for free. **Registration can be waived in special cases (Please bring in your MLU/UKH ID card)**

**Bank name:**
Deutsche Apotheker- und Aerztebank
IBAN: DE46300606011008814171
SWIFT code: DAAEDEDD

reason for payment: name, reg. fee TIMO XII

**SYMPOSIUM SECRETARY:**
Sylvi Magdeburg
Institute of Medical Immunology
Martin Luther University Halle-Wittenberg
Magdeburger Straße 2, 06097 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055
e-mail: immunologie@uk-halle.de

The Medical Association of Saxony-Anhalt credits this educational activity with 7 points (workshop) and 12 points (symposium). You will receive a certificate of attendance on site at the registration desk.

---

**Symposium program „Tumor immunology”**

**Date:** 06th of May 2017

**Venue:** University Hospital Halle, Building 6, Lecture Hall
Ernst-Grube-Straße 40, 06120 Halle

**Session: Novel immunotherapeutic strategies and resistance mechanisms**
Chair: John Hiscott / Peter Fasching

08.30 – 09.00 a.m.
A look into melanoma immune resistance mechanisms
Gal Markel (Tel Aviv, IL)

09.00 – 9.30 a.m.
Role of epigenetic alterations in tumors and their modulation by demethylating agents
Anna Maria Giacomo (Siena, I)

09.30 – 10.00 a.m.
The other side of anti-CD20 antibodies: activation of Fc receptors by anti-CD20 antibodies in CLL
Shlomo Elias (Jerusalem, IL)

10.30 – 11.00 a.m. **Coffee break**

**Session: Combination therapy**
Chair: Sergio Rutella / Gal Markel

10.30 – 11.00 a.m.
Targeting the sentinel lymph node for the treatment of early-stage tumors
Tanja de Gruijl (Amsterdam, NL)

11.00 – 11.30 a.m.
Natural products, a smart rational approach to combination immune therapy
Samir Khleif (Augusta, USA)

11.30 – 12.00 p.m.
Conventional CARs versus modular CARs
Michael Bachmann (Dresden, GER)

12.00 – 12.30 p.m.
Wrap up and closing remarks
**Poster session „Tumor immunology“**

*Date:* 05th of May 2017, 12.45 – 02.00 p.m.

*Venue:* University Hospital Halle, Building 6, Lobby
Ernst-Grube-Straße 40, 06120 Halle

---

**POSTER SESSION**

*Chair:* Greta Guarda / Shlomo Elias

1. Mitochondrial reactive oxygen species sensitize T-ALL cells to apoptosis by engaging the OMA1-OPA1 axis
   Gloria Scattolin (Padua, I)

2. Redox reactive seleno compounds as anti-cancer therapeutics
   Claudia Lennicke (Halle, GER)

3. Pro-oxidant tumor therapy in murine melanoma and pancreatic cancer
   Sander Bekeschus (Greifswald, GER)

4. Study of metabolic heterogeneity of tumors at clonal level and its modulation by anti-angiogenic therapy
   Martina Tognon (Padua, I)

5. Effects of 2-hydroxyglutarate on DC activation
   Elizabeth Cárdenas-Conejo Zugey (Regensburg, GER)

6. Identification of microRNAs affecting recognition of melanoma cells by tumor antigen specific CD8+ T cells
   Antonio Pane (Heidelberg, GER)

7. Altered T cell recognition of long-term BRAF inhibitor-treated melanoma cells
   Fang Zhao (Essen, GER)

8. Phenotype of infiltrating human 6-sulfo LacNAc dendritic cells in renal cancer
   Rebecca Wehner (Dresden, GER)

   Claudia Wickenhauser (Halle, GER)

10. Nanostring analysis as a novel method for immune monitoring of checkpoint inhibitor therapies
    Jürgen Bukur (Halle, GER)

11. Triple negative breast cancer in Africa - a joint collaboration of the Universities Halle, Addis Ababa and Bamako
    Brahim Malle // Zelalem Woldesonbet // Meron Yohannes (Addis Ababa, ETH)

12. Subtype-specific prognostic impact of different gene expression signatures in node-negative breast cancer
    Anne-Sophie Heimes (Mainz, GER)

13. TILGen study – Identification of tumor specific mutations for cell based immunotherapy of breast cancer patients
    Hanna Huebner (Erlangen, GER)

14. Therapeutic potential of mesenchymal stem cells and cytotoxic T cells analyzed using tumor spheroids
    Svenja Rühland (Munich, GER)

15. Engineering human regulatory T cells with a novel modular chimeric antigen receptor technology
    Alexandra Kegler (Dresden, GER)

16. Retargeting of T lymphocytes to GD2 expressing tumors using the novel switchable CAR platform technology “UniCAR”
    Nicola Mitwasi (Dresden, GER)

17. Characterization of NF-κB-optimized dendritic cells expressing the truncated large T antigen Merkel cell polyomavirus for therapeutic vaccination against Merkel cell carcinoma
    Kerstin Gerer (Erlangen, GER)
**WE THANK OUR SPONSORS:**

Astra Zeneca GmbH (1.500 €), Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000 €), CDDF (Cancer Drug Development Forum) (2.500 €), City of Halle, CureVac (2.000 €), Deutsche Forschungsgemeinschaft (DFG), Deutsche Gesellschaft für Immunologie (DGfI), Epiontis GmbH, Essen BioScience Ltd, Life Science Solutions PerkinElmer, Lipocalyx GmbH, Merck Serono GmbH (750 €), Miltenyi Biotec GmbH, nanoString Technologies, Novartis Pharma GmbH (750 €), Pfizer Pharma GmbH (1.000 €), Qiagen GmbH, Sarstedt, Sciomics GmbH, SERVA GmbH, Society for Immunotherapy of Cancer

**CONFERENCE VENUE:**

University Hospital Halle
Ernst-Grube-Strasse 40; 06120 Halle
Building 6, Lecture Hall

**Airport or main train station transportation:**

Various taxi companies service the airport Leipzig or the main train station Halle. A cab ride costs approx. 45 € from the airport to the clinic and from the train station to the Conference venue approx. 8 €. In addition, public train service is available from the airport to Halle (every 30 min.).

From the main train station in Halle you can take the tram no. 4 or 5, direction Heide or Kroellwitz.

**PARKING INFORMATION:**

Several parking facilities are located next to the Ernst-Grube-Street. Please follow the sign „Parkplatz Universitätsklinik“.

**PHOTOS:**

*Photos by © Michael Hoetzel, DGPh*
Institute of Medical Immunology

Prof. Dr. Barbara Seliger
Director of FOCIS Center of Excellence

Martin-Luther-University Halle-Wittenberg
Medical Faculty
Magdeburger Straße 2
06112 Halle (Saale)

Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055

e-mail: immunologie@uk-halle.de